Median Technologies Secures €37.5 Million Financing Deal with European Investment Bank to Advance AI-Based Cancer Diagnostics

Median Technologies, a French company specializing in AI-powered medical devices for early cancer diagnosis, has secured a new financial agreement with the European Investment Bank (EIB) for up to €37.5 million. The agreement, signed on July 11, 2025, is part of a series of discussions that began earlier this year in January and April, aimed at enhancing Median’s financial and operational capabilities. Fredrik Brag, CEO and Founder of Median Technologies, expressed his satisfaction with the new financing facility. “We are honored to be part of the European innovative ecosystem supported by the EIB, and these funds will strengthen our financial independence to negotiate the best commercialization options for eyonis® LCS in the U.S. and Europe,” he stated. Financing Facility Structure The EIB financing facility is structured in three tranches: - Tranche A: €19 million, to be drawn down once all contractual conditions are met. This includes securing additional equity financing of at least €10 million by June 30, 2026. - Tranche B: €8.5 million, available at Median’s discretion, subject to specific conditions. - Tranche C: €10 million, also discretionary and subject to conditions. Upon drawing the first tranche, Median will issue warrants whose quantity and exercise price will be determined by the stock price at the time of issuance. If the current trading stock price holds, the warrants could represent up to 10% of the company’s share capital. Intended Use of Proceeds The EIB funds will primarily support the commercial launch and sales development of eyonis® Lung Cancer Screening (LCS) in the United States and Europe. Additionally, the funds will accelerate the development of Median’s proprietary eyonis® suite for early cancer diagnosis, focusing on: - eyonis® IPN: For the detection and management of incidental pulmonary nodules. - eyonis® HCC: For early diagnosis of primary liver cancer. Regulatory and Commercial Progress Median Technologies is making significant strides in regulatory and commercial preparations: - Regulatory Filings: The company is working on marketing authorization filings with the FDA and European regulatory bodies. Once these are secured, commercial launches can proceed. - Strategic Partnerships: Median is in talks with leading AI-diagnostic and imaging equipment manufacturers to finalize commercialization agreements. Key U.S. healthcare institutions, identified through a comprehensive market analysis, are anticipated to drive the initial commercial success of eyonis® LCS. - Payer Discussions: These will commence upon FDA approval, leveraging preliminary studies that show economic benefits. Median has already mapped out key U.S. payers and demonstrated how eyonis® LCS can enhance early detection, reduce unnecessary procedures, and save costs. - Health Economics Studies: Following regulatory approvals, Median plans to launch further health economics studies, engaging with early adopters and key opinion leaders who have shown interest in the technology. About Median Technologies Median Technologies is a pioneer in AI-driven Software as a Medical Device (SaMD) and imaging services, enhancing the accuracy of early cancer diagnoses and treatments. Its flagship product, eyonis®, includes tools for lung cancer screening, incidental pulmonary nodule detection, and primary liver cancer diagnosis. Median also offers iCRO, a service for medical image analysis and management in oncology trials. Headquartered in Sophia Antipolis, France, with operations in the U.S. and China, Median trades on the Euronext Growth market under the ticker ALMDT. Industry Insider Evaluation The investment from the EIB is seen as a strong endorsement of Median’s innovative approach and potential impact in the field of oncology diagnostics. Industry experts highlight the critical role of high-quality, AI-powered diagnostic tools in improving patient outcomes and reducing healthcare costs. The additional funding is expected to bolster Median’s ability to navigate regulatory hurdles and scale its commercial operations, positioning it as a key player in the rapidly evolving AI healthcare market. Meta’s recent investment in data labeling company Scale AI underscores the broader trend of tech giants investing in specialized AI firms to stay competitive. For Median, this injection of capital is crucial for advancing its cutting-edge technology and ensuring it remains at the forefront of early cancer detection and treatment.